Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on June 13 - 17, 2014 in San Fr

 Oramed Pharmaceuticals to Present at the American Diabetes Association 74th
          Scientific Sessions on June 13 - 17, 2014 in San Francisco

PR Newswire

JERUSALEM, June 10, 2014

JERUSALEM, June 10, 2014 /PRNewswire/ --



Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
clinical-stage pharmaceutical company focused on the development of oral drug
delivery systems, announced today that three scientific abstracts summarizing
studies performed with ORMD-0801, its orally ingestible insulin capsule, were
accepted for inclusion at the American Diabetes Association 74^th Scientific
Sessions, which will take place in San Francisco.

Two abstracts will be presented at poster sessions and all three will be
published in the Scientific Sessions Abstract Book. The posters will be
attended by Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

Abstract Information

1. Title:Comparative Assessment of the Glucose-Lowering Effect of Multiple
Oral Insulin (ORMD-0801) Formulation Variants in Pigs (for publication only)

2. Title:Bedtime Oral Insulin Lowers Fasting Blood Glucose Levels in T2DM
Patients

Poster Session: Sunday, June 15th, 2014, 12pm-2pm Pacific time, Hall D

3. Title: Improved Oral Insulin Bioavailability when Delivered in Soft
Capsules

Poster Session: Sunday, June 15th, 2014, 12pm-2pm Pacific time, Hall D

About the American Diabetes Association (ADA) Scientific Sessions

The ADA's Scientific Sessions brings together scientists and health care
professionals

from around the world who are involved in diabetes research and care. The
five-day

meeting features the most timely and significant advances in the prevention,
diagnosis,

and treatment of diabetes. The program includes presentations by
world-renowned diabetes experts.

For more information on the ADA, please refer to their website:
http://www.diabetes.org. More information on the Scientific Sessions can be
found at
http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229

About ORMD-0801 Oral Insulin

Oramed's ORMD-0801 is an orally ingestible insulin capsule for the early
stages of type 2 diabetes, when it can still slow the rate of degeneration of
the disease by providing additional insulin to the body and allowing
pancreatic respite. Moreover, orally administered insulin has the potential
benefit of enhanced patient compliance at this crucial stage as well as the
advantage of mimicking insulin's natural location and gradients in the body by
first passing through the liver before entering the bloodstream. For more
information on ORMD-0801, the content of which is not part of this press
release, please visit: http://oramed.com/index.php?page=14,

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs currently delivered via injection. Established in 2006,
Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of
research by top research scientists at Jerusalem'sHadassah Medical Center.
Oramed is seeking to revolutionize the treatment of diabetes through its
proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently in separate Phase II clinical trials in patients with both type 1
and type 2 diabetes under an Investigational New Drug (IND) application with
the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering
IND-enabling studies later this year.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and other federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates" and
similar expressions or variations of such words are intended to identify
forward-looking statements. For example, we are using forward-looking
statements when we discuss our clinical trials, including the expected design
or timing thereof, the effects of ORMD-0801 and oral insulin in general, and
revolutionizing the treatment of diabetes with our products. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals    
Aviva Guiloff        
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: aviva@oramed.com

USInvestor Relations Contact:
LifeSci Advisors LLC
Andrew McDonald
US: +1-646-597-6987
Email: andrew@lifesciadvisors.com

SOURCE Oramed Pharmaceuticals
 
Press spacebar to pause and continue. Press esc to stop.